Markers for cardiovascular disease in monozygotic twins discordant for the use of third-generation oral contraceptives
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Markers for cardiovascular disease in monozygotic twins discordant for the use of third-generation oral contraceptives. / Loos, R J F; Verhaeghe, J; De Zegher, F; Beunen, G; Derom, C; Fagard, R; Mathieu, C; Vlietinck, R.
I: Journal of Human Hypertension, Bind 17, Nr. 7, 07.2003, s. 481-5.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Markers for cardiovascular disease in monozygotic twins discordant for the use of third-generation oral contraceptives
AU - Loos, R J F
AU - Verhaeghe, J
AU - De Zegher, F
AU - Beunen, G
AU - Derom, C
AU - Fagard, R
AU - Mathieu, C
AU - Vlietinck, R
PY - 2003/7
Y1 - 2003/7
N2 - Oral contraceptives (OC) modulate the risk for developing cardiovascular (CV) diseases. The aim of this study was to determine whether the use of third-generation OC has an impact on markers of CV disease in genetically identical women. We performed an intrapair comparison in 27 monozygotic twin pairs, one of whom was taking third-generation OC, whereas the other was not using OC. Biometric parameters were ascertained and conventional and 24-h ambulatory blood pressure (BP) was recorded. A fasting blood sample was taken for the measurement of glucose, insulin, proinsulin, lipids, and insulin-like growth factor binding protein-1 (IGFBP-1). Insulin resistance and beta-cell function were calculated by homeostasis model assessment (HOMA). A 24-h urine sample for cortisol was obtained. Third-generation OC use increased 24-h ambulatory systolic and diastolic BP by 5.2 and 3.9 mmHg, respectively (both P=0.0003). There was no effect on glucose, insulin and proinsulin levels, and on HOMA parameters, but the IGFBP-1 levels were markedly raised (P=0.0009). The lipid profile showed a 34% increase in triglyceride levels (P < 0.0001), but also a 7% increase in HDL-cholesterol levels (P=0.037). Use of third-generation OC impacts on CV disease markers in young-adult genetically identical women. Some changes are beneficial (increased HDL-cholesterol), whereas others may be deleterious (increased BP and triglyceride levels) or have unknown effects at this time (increased IGFBP-1 levels).
AB - Oral contraceptives (OC) modulate the risk for developing cardiovascular (CV) diseases. The aim of this study was to determine whether the use of third-generation OC has an impact on markers of CV disease in genetically identical women. We performed an intrapair comparison in 27 monozygotic twin pairs, one of whom was taking third-generation OC, whereas the other was not using OC. Biometric parameters were ascertained and conventional and 24-h ambulatory blood pressure (BP) was recorded. A fasting blood sample was taken for the measurement of glucose, insulin, proinsulin, lipids, and insulin-like growth factor binding protein-1 (IGFBP-1). Insulin resistance and beta-cell function were calculated by homeostasis model assessment (HOMA). A 24-h urine sample for cortisol was obtained. Third-generation OC use increased 24-h ambulatory systolic and diastolic BP by 5.2 and 3.9 mmHg, respectively (both P=0.0003). There was no effect on glucose, insulin and proinsulin levels, and on HOMA parameters, but the IGFBP-1 levels were markedly raised (P=0.0009). The lipid profile showed a 34% increase in triglyceride levels (P < 0.0001), but also a 7% increase in HDL-cholesterol levels (P=0.037). Use of third-generation OC impacts on CV disease markers in young-adult genetically identical women. Some changes are beneficial (increased HDL-cholesterol), whereas others may be deleterious (increased BP and triglyceride levels) or have unknown effects at this time (increased IGFBP-1 levels).
KW - Adult
KW - Biomarkers
KW - Blood Glucose/analysis
KW - Blood Pressure
KW - Blood Pressure Monitoring, Ambulatory
KW - Cardiovascular Diseases/chemically induced
KW - Contraceptives, Oral, Combined/adverse effects
KW - Diseases in Twins
KW - Female
KW - Humans
KW - Hydrocortisone/urine
KW - Insulin/blood
KW - Insulin Resistance
KW - Insulin-Like Growth Factor Binding Protein 1/blood
KW - Lipids/blood
KW - Progestins/adverse effects
KW - Proinsulin/blood
KW - Twins, Monozygotic
U2 - 10.1038/sj.jhh.1001578
DO - 10.1038/sj.jhh.1001578
M3 - Journal article
C2 - 12821955
VL - 17
SP - 481
EP - 485
JO - Journal of Human Hypertension
JF - Journal of Human Hypertension
SN - 0950-9240
IS - 7
ER -
ID: 258451960